Enliven Therapeutics (ELVN) vs Disc Medicine (IRON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Enliven Therapeutics (ELVN) has outperformed Disc Medicine (IRON) over the past year, gaining 113.9% versus a loss of 18.9%. Over five years, ELVN leads with a +254.6% price change compared with -14.2% for IRON. Enliven Therapeutics is the larger company by market cap ($3.42 billion vs $3.42 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELVN | IRON |
|---|---|---|
| Share price | $46.53 | $75.14 |
| Market cap | $3.42B | $3.42B |
| 1-day change | +0.26% | -1.27% |
| YTD return | +202.14% | -5.38% |
| 1-year return | +113.93% | -18.86% |
| 5-year return | +254.65% | -14.22% |
| EPS (TTM) | $-1.69 | $-6.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-103.69M | $-212.18M |
| 52-week high | $62.32 | $99.50 |
| 52-week low | $14.79 | $40.00 |
| Distance from 52-week high | -25.34% | -24.48% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +59.75% | +69.94% |
| Average volume | 1.36M | 951.56K |
| Shares outstanding | 73.60M | 45.54M |
| Employees | 65 | 173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELVN has outperformed IRON by 132.8 percentage points over the past year.
About Enliven Therapeutics
ELVN stock →Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 173 employees
ELVN vs IRON FAQ
Which is bigger, Enliven Therapeutics or Disc Medicine?
Enliven Therapeutics (ELVN) is larger, with a market capitalization of $3.42B compared with $3.42B for Disc Medicine (IRON).
Which stock has performed better over the past year, ELVN or IRON?
ELVN returned +113.93% over the past 12 months, compared with -18.86% for IRON (price return, excluding dividends). Past performance does not predict future results.
Are Enliven Therapeutics and Disc Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.